Fe₂O₃-based nanozyme synergistic with oseltamivir for broad-spectrum inhibition of influenza A virus.

Yongkang Li; Yuqing Jiang; Yun Zhang; Sun Y; Chong Zhang; Yue Wang; Yuanguo Li; N Li; Z M Wang; Butian Zhang; Weiyang Sun; Xiuxia He

doi:10.1016/j.intimp.2026.116753

April 30, 2026

Fe₂O₃-based nanozyme synergistic with oseltamivir for broad-spectrum inhibition of influenza A virus.

View at Publisher

Ask AI

Bookmark

Share

Key Points

This study aims to explore the synergistic effects of Fe2O3-based nanozymes combined with oseltamivir for inhibiting Influenza A virus.
Developed Fe2O3-based nanozyme as an antiviral agent.
Evaluated the effectiveness of nanozyme in conjunction with oseltamivir against various subtypes of Influenza A.
Conducted in vitro assessments to measure inhibition levels.
Fe2O3-based nanozyme shows significant enhancement in antiviral activity when combined with oseltamivir.
Demonstrated broad-spectrum inhibition of multiple Influenza A virus subtypes.
Effective therapeutic potential identified for combined treatment approach.

Implication

Novel strategy combines nanomaterials with oseltamivir to inhibit influenza A virus in antiviral therapies.

Abstract

-OTV is a broad-spectrum inhibitor against different subtypes of influenza A viruses. This study presents a novel strategy for the application of nanomaterials in antiviral therapeutics.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/69f8380b3ed186a739982630 https://doi.org/10.1016/j.intimp.2026.116753

View at Publisher

Ask AI

Bookmark

Share

Fe₂O₃-based nanozyme synergistic with oseltamivir for broad-spectrum inhibition of influenza A virus.

Key Points

Implication

Abstract

Discussion

Cite This Study

Fe₂O₃-based nanozyme synergistic with oseltamivir for broad-spectrum inhibition of influenza A virus.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading